CLLS · NASDAQ
Cellectis (CLLS) Stock Price & Fundamentals
Cellectis (CLLS) closed at $388.37 on Oct 9, 2026, down 0.63% from the previous close of $390.85.
Share price, past year
1Y −11.11%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $388.37 |
| Sep 30, 2026 | $380.86 |
| Aug 31, 2026 | $394.34 |
| Jul 31, 2026 | $414.23 |
| Jun 30, 2026 | $431.80 |
| May 29, 2026 | $430.55 |
| Apr 30, 2026 | $409.32 |
| Mar 31, 2026 | $396.78 |
| Feb 27, 2026 | $409.92 |
| Jan 30, 2026 | $428.43 |
| Dec 31, 2025 | $445.33 |
| Nov 28, 2025 | $420.81 |
| Oct 31, 2025 | $431.60 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- —
- Dividend yield
- —
- 52-week range
- $380.86 – $457.16
Market cap, P/E and dividend yield aren't shown for Cellectis yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US.
Financials
Cellectis reported revenue of $72.95M for fiscal 2025, up 75.76% from fiscal 2024.
Cellectis reported a net loss of $67.59M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $72.95M | +75.8% | −$67.59M | −92.7% | −$0.67 | −$41.76M |
| FY2024ended Dec 31, 2024 | $41.51M | +5,397.4% | −$36.76M | −88.6% | −$0.41 | $20.41M |
| FY2023ended Dec 31, 2023 | $755.00K | −96.1% | −$101.06M | −13,385.3% | −$1.77 | −$25.82M |
| FY2022ended Dec 31, 2022 | $19.17M | −36.8% | −$106.14M | −553.6% | −$2.33 | −$89.88M |
| FY2021ended Dec 31, 2021 | $30.35M | −40.6% | −$114.20M | −376.3% | −$2.55 | −$123.11M |
| FY2020ended Dec 31, 2020 | $51.06M | +236.1% | −$81.07M | −158.8% | −$1.91 | −$124.34M |
| FY2019ended Dec 31, 2019 | $15.19M | +19.3% | −$102.09M | −672.1% | −$2.41 | −$82.06M |
| FY2018ended Dec 31, 2018 | $12.73M | −49.5% | −$78.69M | −618.1% | −$1.93 | −$72.85M |
| FY2017ended Dec 31, 2017 | $25.19M | −43.8% | −$99.37M | −394.5% | −$2.78 | −$54.71M |
| FY2016ended Dec 31, 2016 | $44.81M | — | −$67.26M | −150.1% | −$1.91 | −$46.41M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2025ended Jun 30, 2025 | $16.73M | −$23.74M | −$0.24 |
| Q2 FY2024ended Jun 30, 2024 | $8.06M | −$25.27M | −$0.28 |
| Q2 FY2023ended Jun 30, 2023 | $178.00K | −$11.71M | −$0.20 |
| Q2 FY2022ended Jun 30, 2022 | $1.31M | −$18.95M | −$0.42 |
| Q2 FY2021ended Jun 30, 2021 | $11.18M | −$39.92M | −$0.88 |
| Q2 FY2020ended Jun 30, 2020 | $2.90M | −$32.26M | −$0.76 |
| Q2 FY2019ended Jun 30, 2019 | $1.15M | −$33.45M | −$0.79 |
Company profile
- Name
- Cellectis S.A.
- Ticker
- CLLS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 8 Rue De La Croix Jarry, Paris, Lle-De-France
- Incorporated in
- I0
- Fiscal year ends
- December
- SEC CIK
- 0001627281
Recent SEC filings
- Mar 20, 2026
- Mar 14, 2025
- Mar 14, 2025
- Apr 29, 2024
- Oct 31, 2023
- Mar 14, 2023
- Mar 3, 2022
- Mar 4, 2021
Frequently asked questions
What is Cellectis's stock price?
Cellectis (CLLS) closed at $388.37 on Oct 9, 2026, down 0.63% from the previous close of $390.85.
How much revenue does Cellectis make?
Cellectis reported revenue of $72.95M for fiscal 2025, up 75.76% from fiscal 2024.
Sources and methodology
Fundamentals come from Cellectis S.A.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures